Abstract: To study the eff ectiveness of vascular endothelial growth factor (VEGF) added with biphasic calcium phosphate (BCP) on the expression of osteogenesis and angiogenesis-related gene in dental stem cells (DSCs). The cells were treated with three diff erent modalities; BCP group, VEGF group, and VEGF-added-BCP. The optimal BCP and VEGF concentrations were determined. The cells were harvested at four diff erent time intervals (day 3, day 7, day 10 and day 14) and were subjected to RNA isolation. Osteogenesis and angiogenesis-regulated genes was amplifi ed using reverse transcriptase-PCR (RT-PCR). The RT-PCR products were then electrophoresed. The gel images were captured using Image Analyser AlphaEaseFC™. Angiogenesis and osteogenesis genes were clearly expressed in DSCs in response to treatments with 75mg/ml BCP and 5ng/ml VEGF. Angiogenesis gene VEGF was highly expressed by VEGF treatment group but showed some changes when added with BCP. Osteogenesis genes (BMP-2 and OPN) were positively aff ected by both BCP and VEGF. Some genes were expressed at an earlier time interval compared to the other genes depending on the type of treatments. BCP treatment induced high expression of initial-regulated osteogenesis genes (BMP-2 and OPN). Combination of BCP and VEGF modality on DSCs was suggested to initiate osteogenesis and angiogenesis-related gene expressions earlier than the other modalities. In our design, uncontrolled release of VEGF protein showed inhibition of BMP-2 at mRNA level in VEGF-BCP combined group.
Introduction
Dental stem cells (DSCs) in particular, hold great promise to bone tissue strategies due to their advantages with high proliferation rate ability makes it a good tool that goes far beyond regenerative medicine and considered excellent candidate stem cells for hard and soft tissues regeneration and organ transplantation in bone tissue engineering. DSCs treated with appropriate cues could diff erentiate into osteoblasts, endothelial cells (ECs), chondroblasts, neural and smooth muscle cells similar to that of other types of mesenchymal stem cells (MSCs) 1) .
Recently, studies indicate that the human dental tissue contains precursor cells, named dental stem cells DSCs that offer advantages because of lower morbidity during the harvesting procedure and show self-renewal and multilineage diff erentiation capacity 2, 3) . DSCs have the ability to generate not only dental tissues but also bone tissues. The success of tissue engineering depends on oxygen and nutrient transport to the implanted cells 2, 4) . If blood vessel formation at the transplanted tissue cannot be established rapidly, necrosis of the transplant will occur 5) . Therefore, in order to evaluate human DSCs are good candidates for tissue engineering, it is of utmost importance to investigate the eff ectiveness of these stem cells to induce angiogenesis and osteogenesis 2) . In addition, under appropriate conditions, DSCs have a superior immunoregulatory capacity that abolishes T-cell alloreactivity than bone marrow-MSCs, may not elicit humoral immune responses. Thus it is immune privileged 6, 7) . This finding plus their high proliferative ability makes DSCs a good candidate for tissue engineering and organ transplantation 8) . Biodegradable BCP is considered as a good scaffold for bone substitution for tissue regeneration. VEGF is a key regulatory molecule that promotes the growth of new blood vessels by acting in ECs with a powerful mitogenic activity 5) . Due to their high proliferation rate and efficiency in producing bone chips, DSCs seem to be the best attractive candidates to study bone formation with respect to bone marrow-MSCs 9) . In tissue regeneration, it is important to consider the possible impact of the combination of the scaff old and the stimulator on processes linked to cell proliferation and function. Angiogenesis, the formation of capillaries from pre-existing blood vessels, is a key process in tissue engineering. If blood supply cannot be established rapidly, there is insuffi cient oxygen and nutrient transport and necrosis of the implanted tissue will occur. This type of blood vessel Formed cells pellet was re-suspended in 3 ml culture medium. The solution was pipette up and down for a few min. Fifteen ml DMEM media and 1 ml of cell suspension was added to three T-75 cm 2 fl asks.
It was checked under the microscope, and incubated again at 37°C, 5% CO 2 , and 95% humid atmosphere. Cells were monitored closely for 24 hours. Cells were washed with PBS two times. After washing the cells were detached from the bottom of the tube with trypsin solution.
It was re-suspended in DMEM by centrifugation. Cell suspension was adjusted to 1×104 cells/ml. It was inoculated on a 96-well plate with 200 μl of suspension per well, and incubated for 24 hours for cell adhesion.
Biocompatibility test
Extracts for indirect tests obtained from BCP powder under standardized conditions were based on references from International standards (ISO 10993 part 5, 2009) 11) . The solvent used for extracting BCP powder was DMEM. DSCs were exposed to varying concentrations of BCP-treated media. Serial dilutions of 75, 50 and 25mg/ml (vol/vol) from the pure extract were prepared, and DSCs of passage 4 were collected. Culture medium was discarded when the primary cell monolayers were grown until 80% to 90% confluence. Cells were washed with PBS two times vigorously. Sub-culturing by cell passage was performed by trypsinization. For detaching the cells from the fl ask it was incubated at 37°C for 2 min to 3 minutes. Trypsin cleaves the proteins that link the cells to the extra-cellular matrix.
Cell counting was performed using haemocytometer by trypan blue Merck, GermanyAjax Finechem Pty Ltd to determine viable (living) vs. nonviable (dead) cells (the dye cannot be absorbed by viable cells). For each experiment, cells were lysed and pipetted into a 96-well plate with standardized cell number. Treated media at 90μl from each concentration and untreated media for the control group were used in each well plate, followed by incubation in 95% humid atmosphere of 5% CO 2 at 37°C. Viability assessment at diff erent time points (1, 3 and 7 days) after incubation was done. For viability assessment, we choice PrestoBlue® cell viability reagent (Gibco, USA) (PB) in our study because it is more rapidly effi cient developed a color change compared with other reagents 12) . PrestoBlue reagent protocol 10µl was added for each well under the dark fi eld. Again Incubate with same standardized condition for 2 hrs using aluminum foil to protect it from light. ELISA readerTecan was used, and absorbance was read at 570 and 600 nm as reference wavelength The experiment was repeated thrice.
Optimizing the VEGF concentration and RT-PCR
The optimal concentration of VEGF for the induction gene expression in DSCs was determined in the Craniofacial Lab, School of Dental Sciences, USM. The fi nal concentrations of VEGF used in this experiment were: 5, 10, 20 and 50 ng/ml. Cells cultured with untreated media were used as a control and followed the manufacturing protocol. RNA extraction kit (Analytik Jena AG, Konrad-Zuse-Strasse 1, 07745 Jena, Germany) was used after preparation and the experiment was repeated 3 times. Because Buff er RPE was supplied as a concentrate, 4 volumes of ethanol (96-100%) were added to Buffer PRE before using for the fi rst time to obtain a working solution as indicated by the company instructions. The samples (the cell pellets) were retrieved from the ices and 350 µl of RLT buffer were added to each sample. Cellular RNA was totally extracted by followed RNA extraction kit provides by the supplier. The concentration and purity of total cellular RNA were evaluated by measuring the absorbance at 260 nm (A260) and 280 nm (A280) using spectrophotometer (Biophotometer, Eppendorf AG, Hamburg, Germany). 374 development is indispensable for physiological processes such as wound healing and reproduction 2) . VEGF exerts its effects through induction of vascularization which in turn plays an important role in bone growth and development. It also supports the survival and activity of bone-forming cells as well as migration and differentiation of primary human osteoblasts 10) . Therefore this study aimed to evaluate the eff ectiveness of VEGF added BCP on the expression of osteogenesis and angiogenesis related gene in DSCs. ). It was incubated at 37°C in 5% CO 2 and 95% humid environment. After every three days the DMEM was changed. Before passage the confl uence of the culture was allowed to reach approximately 80-90%. Following harvest by trypsinization, the cells were plated in 75cm 2 cultured flask. DSCs were expanded by repeated passage, and each T-75cm 2 fl ask at 80% to 100% confl uence was plated into three fl asks.
Materials and Methods
Cell passage was continued according to the demand of the experiment. The cells were counted and cryopreserved in liquid nitrogen until use. DSCs passage and subculture were conducted when the cells reached 80% to 100% confluence. Under an inverted light microscope, the media were checked for contamination (change in color or turbidity). The medium was removed and washed with PBS twice for the cell passage. Up to 2ml trypsin (0.25) was added (T-75cm2 flask) and samples were incubated in 37°C and 5% CO 2 for 3 to 5 minutes. The detached cells were observed under a microscope for their attachment. In case cells were still attached, the flask was incubated and gentle movement was applied to dislodge the cells. The flask was checked again until 90% of cells became rounded and were detached from the fl ask. Pre-warmed medium (5 ml) at 37°C was added to the fl ask for neutralization of trypsin action. By continuous gentle pipetting the cell were spread into a single 2 culture fl ask. Morphology of the cells was observed daily under inverted light microscope using 5 x lenses. cell suspension on the surface of the flask. The cell suspension was transferred to a centrifuge tube and centrifuged at 1,000 rpm for 5 minutes. Supernatant obtained from the centrifuge tube was discarded.
Osteogenesis and angiogenesis gene expressions experiments
After determining the optimal concentration of BCP and VEGF, DSCs were treated with three different modalities; BCP only, VEGF only, and VEGF-BCP combined. The cells were collected on days: 3, 7, 10 and 14. Diff erent initial numbers of cells were used for diff erent days. The cells numbers were: 300 x 10 3 cells for day 3, 25 x 10 3 for day 7, 10 x 10 3 cells for day 10 and 10 x 10 3 cells for day 14. The cells were harvested at four diff erent time intervals (day 3, 7, 10 and 14) and subjected to RNA isolation using RNA extraction kit. This study was conducted to evaluate the specific biological activities within the DSCs cultured in media treated with BCP with and without the addition VEGF. Gene expressions were analyzed using RT-PCR technique. Angiogenic and osteogenic gene expressions were assessed at mRNA level. Amplification of osteogenesis and angiogenesis target gene was performed by one-step RT-PCR, which was prepared according to the recommendations by the manufacturers (RNeasy®, Qiagen, USA). RT-PCR was performed using specific primers; the housekeeping gene used in this study was GAPDH. Onestep RT-PCR master mix preparation was prepared, and the total volume per RT-PCR reaction was 25 μl of the total RNA,0.2 μg was used in the RT-PCR reaction. The protocol followed for one-step RT-PCR was in accordance with the recommended procedure. Angiogenic and osteogenic gene expressions were assessed at mRNA level including A The optimal concentration of VEGF, growth factor protein on DSCs based on VEGF gene expression was determined by using KruskalWalis test. The comparison was between 5, 10, 20, 50 ng/ml and control (0 concentration) at diff erent time points. A p-value of less than 0.05 was considered statistically signifi cant.
Results
Viability test for BCP powder at different concentrations was expressed as relative cell viability that is a percentage of the readings (or activities) in the absence of BCP. The concentration of 75mg/ml BCP treated media showed more proliferation of DSCs compared with other concentrations and control (p<0.05), and 100% cells viability (Fig.  1) . The results of DSCs treated with VEGF showed that 5ng/ml was considered an optimal concentration (p < 0.05) (Fig. 2) .
Osteogenesis and angiogenesis-regulated gene expression analysis
Angiogenesis and osteogenesis genes were clearly expressed in DSCs in response to treatment with BCP, VEGF and VEGF-BCP combined. Angiogenesis gene, VEGF was a marker for DSCs if cultured more than 80% confl uence. VEGF gene was expressed in all groups but highly expressed in VEGF and VEGF/BCP groups. In BCP group, it was highly expressed only at day 14 (Fig. 3) . Osteogenesis gene (BMP-2 and OPN) was shown to be aff ected by both BCP and VEGF. BMP- 1 4 ) , h u m a n B M P - . One-way analysis of variance (ANOVA) was used to perform the cytotoxicity analysis of BCP scaffold in DSCs using different concentrations. Comparisons between groups for the cytotoxicity assay data were analyzed followed by using post hoc test to determine the best concentration at a signifi cance level less than 0.05. p-value of less than 0.05 was considered statistically significant. 2 gene was expressed in all groups. In BCP group, it was expressed at all time points. The expression of BMP-2 gene in VEGF/BCP was higher only on day 3 but showed a reduction on day 7 and repression afterward. However, in VEGF group the BMP-2 gene expression is higher compared to the control group. OPN gene was expressed at all time point in all groups. OPN gene was aff ected positively by BCP and VEGF protein. This is because OPN gene in BCP group was expressed higher in day 3 and day 7 and in VEGF group in day 10 and day 14. A combination of VEGF and BCP showed that the OPN gene was highly expressed in day 3 and moderately expressed in the subsequent days afterward, compared to the control group (Fig. 3) .
VEGF, bone morphogenetic protein-2 (BMP-2) and osteopontin (OPN) respectively. RT-PCR was performed with specific primers as follows: human GAPDH (F) 5'-GACCACAGTCCATGCCATCAC-3' ( R ) : 5 ' -T C C A C C A C C C T G T T G C T G TA G -3 ' ; 1 3 ) , h u m a n V E G F ( F ) : 5 ' -C C C A C T G A G G A G T C C A A C AT-3 ' ( R ) : 5 ' -T T T C T T G C G C T T T C G T T T T T -3 ' ;

( F ) : 5 ' -G A G T T G C G G C T G C T C A G C AT G T T -3 ' ( R ) : 5 ' -A C AT G T C T C T T G G A G
Discussion
The goal of developing novel approach strategies for bone replacement with bone substitutes are focused on stimulation of osteointegration, osteoconduction, osteoinduction as well as induction of angiogenesis and vascularisation 16) . Dental sources MSCs can be applied to obtain suitable autologous DSCs for tissue replacement therapies of both bone and cartilage 17) . DSCs are MSCs in origin in which have a capacity to differentiate into many cell lineages. Runt-related transcription factor-2 (Runx2) is the principal osteogenic master switch, which is involved in the differentiation of MSCs into preosteoblasts stage. Expression of Runx2, which then regulates the expression of Osterix (Osx) in osteoblastic differentiation 18) . Osx is an osteoblastspecifi c transcription factor required for osteoblast diff erentiation and bone formation. A Recent investigation into the molecular pathway of the growth factor signaling via the BMP-2 has shown BMP-2 dependent activation of Osx. Osx was first discovered as a BMP-2 inducible gene in MSCs 19) . Another study established that VEGF transcription in osteoblasts occurs downstream from transcription factor Osx 20) . They established that Osx directly targets VEGF expression and controls osteoblast marker gene. Thus, osteoblasts secrete VEGF in the process of their terminal differentiation, which clearly highlights the crucial role of angiogenesis for bone regeneration. Osx coupled with VEGF regulates expression in osteoblasts and considered a master regulator essential for the commitment of preosteoblastic cell diff erentiation into mature osteoblasts 21) Osx sciption factor is an osteogenic transcription factor vital to the process of bone formation. DSCs are diff erentiating and have the potential to commit to an osteoblastic lineage. On the other hand, direct Figure 4 . A simplified schematic diagram representation of the intracellular signaling pathway (molecular) with diff erent stages of the diff erentiation of dental stem cells (DSCs) into osteoblasts and endothelial cells. The eff ect of exogenous vascular endothelial growth factor (VEGF) may have the ability to arrest osteoblastic diff erentiation in a preosteoblastic stage by inhibiting Osterix (Osx) gene expression bone morphogenetic proteins-2 (BMP-2 inducible gene) for the pre-angiogenesis process. Runt-related transcription factor-2 (Runx2).
cell-cell contact is another way ECs and osteoblasts communicate. In addition, VEGF and ECs specifically have an inhibitory effect on dexamethasone-induced bone marrow-MSCs differentiation (osteogenic inhibitor) into osteoblast, by inhibiting the expression of Osx. The rate of diff erentiation of bone marrow-MSCs to osteoblasts maybe controlled by ECs and VEGF, by initiating the recruitment of osteoprogenitor cells at sites of bone remodeling and maintaining them in a pre-osteoblastic stage, to avoid mineral deposition within the vessel 22, 23) . Osx plays multiple functional roles, the most important of which includes the up-regulation of several genes like BMP-2 and type 1 collagen, these genes encoding for proteoglycans involved in bone mineralization. Osx is osteogenic marker express in osteoblast cell in response to BCP treatment and controls both angiogenesis and osteogenesis 21) . Osx directly targets VEGF expression, whereas Osx controls osteoblast marker gene and coupled with VEGF by regulates expression in osteoblasts. It is considered a master regulator essential for the commitment of preosteoblastic cell diff erentiation into mature osteoblasts 24, 25) . VEGF is an important mediator of angiogenesis and osteogenesis 24) Many cytokine genes are up-regulated in the events of bone repaired. It is thought that both the increased expression of regulatory genes, as well as the later decreased expression of these same genes, are choreographed to promote sequential steps in the healing process (Fig. 4) . OPN gene is known to play an important role in cell attachment and calcification of mineralized tissue. It was confirm to be early and effective markers of bone formation. During the healing process of bone, BMP-2, and OPN mRNA levels, both actively participate during the early stages of bone healing with a peak level at 14 days, indicative of active osteoblastogenesis 26) . OPN is one of the major noncollagenous proteins in bone synthesized and secreted during the process of osteoblast diff erentiation and mineralization and expressed at or near the time of mineralization 27) . BMP-2 expression participated in all phases of bone formation. In our in vitro study, a preselection of the most important genes responsible for regulation of the two critical step in bone healing by mean angiogenesis and osteogenesis. Angiogenesis is closely associated with osteogenesis where reciprocal interactions between endothelial and osteoblast cells play an important role in bone regeneration 28) . It was concluded in the present study, the eff ect of VEGF/BCP on angiogenic and osteogenic marker production was interesting. BCP group showed upregulation in some gene in diff erent time point but fluctuation occur when added VEGF protein, but the effect of treatment modalities on gene expression still controversial. BMP-2 gene showed expression by VEGF group while, BMP-2 gene was expressed only in day 3 but repression occurs at day 7, 10 and 14 in VEGF/BCP group, besides, BMP-2 showed upregulation in BCP group. However, the BMP-2 were, in general, expressed at too low a level to be detectable by RT-PCR in our samples in VEGF-BCP combined group with down regulation from up to day 3 but repression occurred at day 7, 10, 14 in the VEGF-BCP combined with undetectable, mean that BMP-2 inhibit by VEGF action at mRNA level. However, our results confirm with previous findings of Schönmeyr et al. 29) was showed in his work that using of VEGF at high dosage without control release resulting in over expression of VEGF and inhibit BMP-2. VEGF overexpression has the potential to impair bone formation by unbalancing between angiogenesis and osteogenesis. D'Alimonte et al. 30) showed that addition of VEGF to the DSCs in (osteogenic condition) could enhance both osteogenesis and angiogenesis. The current finding showed that only angiogenic enhances with VEGF-BCP combined group but not osteogenic. The work of Tirkkonen et al. 31) strongly agreed with our study fi ndings as he confi rmed that VEGF did not enhance osteogenesis diff erentiation of human adipose stem cells (HASC) by meant BMP-2 inhibition. From this information, it is, therefore, clear that VEGF-BCP culture conditions had signifi cant eff ects in these experiments, but a defi nitive conclusion on angiogenesis and osteogenesis will need to be confi rmed by further studies. Extensive studies in vitro and in vivo, using DSCs with a suitable combination of control release growth factors and scaff old materials, is essential before resorting to human trials. At least three parameters could be considered in order to devise strategies for coupling of these two important processes in bone formation and to preserve the positive effect on vascularization and high quality osteogenesis, while avoiding the negative eff ect on bone formation: 1) the duration of VEGF expression; 2) its dose; and 3) the presence of an osteogenic environment. VEGF expression is required only for about 4 weeks in order to generate persistent vessels 32) .
Threshold dose of VEGF level for normal angiogenesis can be induced over a wide range because control expression at moderate levels might induce eff ective vascularization while limiting osteogenesis achieved 33) .
Purifi ed growth factors are heat and pH unstable and highly sensitive to proteolytic degradation 34) . Therefore, the equilibrium between VEGF triggered angiogenesis, osteogenesis needs to be carefully investigated in controlled release manner of VEGF with low concentration by using long term sustained delivery system meanwhile, concentration in pg/ ml not in ng/ml with respect to the threshold dose consideration proangiogenic potency of VEGF expression. DSCs have the potential to "rephrase" repair craniofacial defects and repair/regenerate teeth 35) .
Protein release is not generally quantifiable for in vivo studies, due to the relatively low concentrations of released protein in blood and tissue samples compared to protein produced naturally by cells in the body. Current study has shown that VEGF protein can inhibit BMP-2 expression at the mRNA level. Delivery of VEGF for in vitro cell culture purposes in bone tissue engineering therefore requires careful optimization and precise delivery of growth factors for regulation of gene expression control both angiogenesis and osteogenesis processes using MSCs. We have shown that uncontrolled release of VEGF protein added BCP can inhibit BMP-2 expression at the mRNA level. Therefore, over expression of VEGF gene showed bad osteogenesis process. Control release of VEGF protein for tissue engineering purposes is necessary for further investigation. Extensive studies in vitro and in vivo using BCP scaff old treated DSCs with control release of biomedical mediator growth factor (in vitro), on animals using DSCs with a suitable combination of growth factors and scaff old materials, is essential before resorting to human trials.
